Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134243 | 0.89 | KCNH2 (0.54) | KCNH2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1619391 | 0.87 | KCNH2 (0.48) | KCNH2USP30ALDH1A1KDM4EPOLB | |
| SCHEMBL4133463 | 0.87 | KCNH2 (0.54) | KCNH2USP30ALDH1A1KDM4ETSHR | |
| SCHEMBL1619314 | 0.86 | KCNH2 (0.72) | KCNH2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL3605800 | 0.86 | KCNH2 (0.72) | KCNH2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4130153 | 0.83 | KCNH2 (0.51) | KCNH2USP30ALDH1A1KDM4E | |
| SCHEMBL4134395 | 0.82 | KCNH2 (0.49) | KCNH2USP30ALDH1A1KDM4E | |
| SCHEMBL4128937 | 0.81 | KCNH2 (0.67) | KCNH2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4134400 | 0.81 | KCNH2 (0.67) | KCNH2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4130161 | 0.81 | KCNH2 (0.56) | KCNH2KDM4EMAPK1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | KCNH2 6/4885USP30 3818/4885MEN1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.